A Double-blind, Parallel-group Phase III Study of TK-041 in Patients with Chronic Urticaria
Phase 3
- Conditions
- Chronic urticaria
- Registration Number
- JPRN-jRCT2080222734
- Lead Sponsor
- TEIKOKU SEIYAKU CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 270
Inclusion Criteria
Chronic urticaria for over a month
Exclusion Criteria
Other skin diseases which interfere with the evaluation
Hypersensitivity to antihistamine drugs or study drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does TK-041 target in chronic urticaria patients in JPRN-jRCT2080222734?
How does TK-041 compare to standard-of-care treatments like omalizumab in chronic urticaria trials?
Are there specific biomarkers associated with response to TK-041 in chronic urticaria phase III studies?
What adverse events were observed in Teikoku Seiyaku's phase III TK-041 trial for chronic urticaria?
What are the potential combination therapies involving TK-041 for chronic urticaria treatment?